Inivata Highlights its InVision ctDNA Assay for Broad Molecular Profiling and Presentation of NSCLC data at ASCO Annual Meeting 2016

June 1, 2016

Inivata Highlights its InVision™ ctDNA Assay for Broad Molecular Profiling and Presentation of NSCLC data at ASCO Annual Meeting 2016

Research Triangle Park, NC, USA and Cambridge, UK – June 1, 2016 – Inivata, a global clinical cancer genomics company employing the precision of circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, will introduce its proprietary InVision™ ctDNA assay for broad molecular profiling during the 2016 Annual Meeting of the American Society of Clinical Oncology (‘ASCO’) at McCormick Place in Chicago, Illinois, June 3-7, 2016.

The InVision™ assay utilizes the innovative application of Inivata’s proprietary enhanced tagged-amplicon sequencing (eTAm-Seq™) platform for genomic analysis, which was developed by Inivata on the basis of the TAm-Seq™ technology from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge. InVision™ was developed to serve as a reliable, multi-gene, support tool for oncologists to accurately translate genomic alterations into actionable information to inform clinical decision making and improve cancer treatment planning for the patient. Commercial availability of the InVision™ assay will be the subject of a future announcement.

At ASCO, clinical data from the InVision™ assay in non-small cell lung cancer is being co-presented with Institut Gustave Roussy. The following abstract will be presented during the poster session:

Abstract Title: Evaluation of liquid biopsies for molecular profiling and monitoring in non-small cell lung cancer (NSCLC) patients. (Abstract #: 11533)

Location: Poster Session:Tumor Biology, Hall A, Board Number 230

Date/Time: June 6th, 1:00 – 4:30pm

Presenter: Jordi Remon, MD

Author affiliations: Institut Gustave Roussy and Inivata

Inivata’s representatives will also be exhibiting and providing further details on the impending commercial launch of the InVision™ assay at the ASCO annual meeting booth number 6161. To arrange an interview or meeting please contact us via info@inivata.com

–ENDS–

Company Contact:

Liz Macfadyen

Email: liz.macfadyen@inivata.com

Phone: +44 (0)7739462323

About Inivata

Inivata, a clinical cancer genomics company, is employing the precision of ctDNA analysis to improve personalised healthcare in oncology. Using a simple blood test, circulating tumour DNA (ctDNA) analysis is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment. Inivata’s proprietary technology is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge. Inivata’s InVision™ ctDNA assay provides a highly sensitive analysis of a strategically selected gene panel to identify actionable mutations for oncologists to treat their patients optimally. For more information and a full listing of investors, please go to www.inivata.com. Follow us on Twitter @Inivata

About ASCO Annual Meeting 2016

The American Society of Clinical Oncology (‘ASCO’) Annual Meeting brings together 30,000 oncology professionals from around the world. Educational sessions feature world-renowned faculty discussing state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Science sessions present the latest ground-breaking research in oral and poster format.

The theme for ASCO 2016 is Collective Wisdom: The Future of Patient-Centered Care and Research.

Discover more news